Metabolic and Hormonal Disorders

Screening and Assessment

• The American Academy of Family Physicians recommends a two-hour oral glucose tolerance test (75g glucose load) for metabolic screening, as well as a fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) and BMI calculation with waist-hip ratio measurement for metabolic screening 1
• The American Academy of Family Physicians suggests assessing total testosterone or bioavailable/free testosterone levels, thyroid-stimulating hormone (TSH) levels, and prolactin levels for hormonal evaluation 1

Monitoring and Prevention

• The American Academy of Family Physicians recommends annual metabolic screening (glucose tolerance, lipid profile, blood pressure) for women with irregular cycles, and monitoring for endometrial hyperplasia in women with irregular cycles 1
• The American College of Obstetricians and Gynecologists recommends lifestyle modification as the first-line therapy for PCOS management, focusing on dietary changes and physical activity to improve metabolic and reproductive outcomes, with a recommended dietary approach including:

2, 3

• Adults with PCOS should aim for 150+ minutes/week of moderate activity or 75+ minutes/week of vigorous activity for general health maintenance, and for weight loss, 250+ minutes/week of moderate activity or 150+ minutes/week of vigorous activity, including muscle-strengthening activities 2 days/week, and targeting 10,000 steps daily and minimizing sedentary time 1, 3

Pharmacological Interventions

• The American Academy of Family Physicians recommends combined oral contraceptives (COCs) as first-line treatment for menstrual irregularities and acne, and anti-androgens (spironolactone, flutamide, finasteride) for hirsutism resistant to first-line treatments 1
• Clomiphene citrate is recommended as first-line treatment for ovulation induction, with approximately 80% of PCOS patients ovulating and half of these conceiving, and low-dose gonadotropin therapy is recommended if clomiphene fails 1
• Metformin is a first-line pharmacological intervention for insulin resistance in PCOS, particularly beneficial for adolescents and women with type 2 diabetes, as recommended by the Endocrine Society 3, 4
• GLP-1 receptor agonists, such as liraglutide and semaglutide, may improve anthropometric outcomes in PCOS patients with obesity, though data is limited 5

Ongoing Management and Monitoring

• Regular monitoring of weight, waist circumference, menstrual cycles, metabolic parameters, and BMI is recommended, with annual assessment of metabolic parameters, including insulin resistance markers, lipid profile, and blood pressure, as suggested by the American Diabetes Association and the American Academy of Family Physicians 1, 3
• Screening for anxiety and depression, and considering the psychological impact of weight management, and providing patient-centered care considering cultural, socio-economic, and ethnic differences is essential, as recommended by the American Psychological Association and the American Academy of Family Physicians 3, 1
• Even modest weight loss (5% of initial weight) can improve metabolic and reproductive abnormalities, and prevention of weight gain is as important as weight loss, emphasizing the importance of lifestyle modifications beyond weight loss alone 1, 3
• Ethnic-specific BMI and waist circumference categories should be considered in the management of PCOS to address diverse health needs, and ethnic groups with PCOS at high cardiometabolic risk require greater attention to lifestyle interventions to mitigate risk factors, as recommended by the Endocrine Society and the American College of Sports Medicine 3

Potential Complications and Risks

• OHSS can occur with clomiphene citrate therapy, especially in patients with PCOS, with early warning signs including abdominal pain and distention, nausea, vomiting, diarrhea, and weight gain, and use of the lowest effective dose and close monitoring is recommended 1